In June, Novant Health announced the creation of its Institute of Innovation & Artificial Intelligence. This week, the North Carolina-based hospital chain tapped Johns Creek, Ga.-based prescriptive analytics provider Jvion to be its inaugural partner in the effort
The institute was launched to help expand the use AI and other emerging technologies to generate data and insights for more personalized and accurate disease prediction, diagnosis and treatment.
According to an announcement the new partners aim to use Jvion’s AI-enable prescriptive analytics tools to integrate clinical and socioeconomic data and, as their initial goal, to reduce readmissions for congestive heart failure (CHF) patients, which reportedly can be as high as 35% in the first year and can double with each subsequent hospitalization.
"Partnering with innovators in analytics such as Jvion allows us to anticipate risk factors and effectively intervene through personalized treatment plans for our patients, saving time and money," said Eric Eskioglu, MD, Novant's executive vice president and chief medical officer, and co-leader of the new institute. "The implementation of this technology will transform the way we deliver care for our patients with CHF across the Carolinas and Virginia, thereby improving their quality of life and preventing unnecessary readmissions.”
According to Jvion, the company’s tools have successfully reduced CHF readmissions by 13 percent on average, preventing 130 readmissions per one thousand discharges for a potential savings of approximately $1 million. Jvion’s “Machine” identifies individual patients at risk, from rising risk to high risk, of avoidable harmful events, the clinical and socioeconomic determinants causing this risk, and personalized interventions that change a patient’s trajectory.
“AI-enabled prescriptive analytics represent a new, innovative approach to using clinical and socioeconomic data to pinpoint the most impactful interventions for individuals suffering from diseases, such as CHF, that can be managed or prevented,” said Shantanu Nigam, Jvion CEO.
Jvion says its Machine pinpoints the impactable patients who are on a risk trajectory that can be changed, then provides patient-specific recommendations that will yield a better outcome. Based on data from 16 million patients and a unique use of Eigen-based models, Novant Health will be able to quickly apply the technology to CHF patients and while also extending its use to additional patient groups.
“With AI-based technologies like Jvion, our care teams can move faster and with more precision to address some of the community’s most serious health concerns – in this case, reducing readmissions for patients with congestive heart failure,” said Angela Yochem, Novant Health executive vice president and chief digital and technology officer.